Treatment of astrocytomas
Javier Gonzalez1, Mark R Gilbert
1MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA.
Current Opinion in Neurology
|November 11, 2005
Summary
Temozolomide combined with radiation improves survival for glioblastoma patients, but these brain tumors remain incurable. Future treatments will focus on biological markers and novel regimens for better outcomes.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Clinical Trials
Background:
- Astrocytomas are the most common primary brain tumors.
- Malignant gliomas represent a significant challenge in neuro-oncology.
- Current treatments offer limited long-term survival for high-grade gliomas.
Purpose of the Study:
- To review recent advancements in astrocytoma biology.
- To examine recent clinical trials for malignant gliomas.
- To highlight progress in improving patient survival rates.
Main Methods:
- Review of current literature on astrocytoma biology.
- Analysis of recent clinical trial data for glioma treatment.
- Synthesis of findings to identify promising therapeutic strategies.
Main Results:
- Temozolomide plus radiation is the standard of care for newly diagnosed glioblastoma.
- Despite current standards, glioblastoma remains largely incurable.
- Biological markers and alternative treatments show potential for improved survival.
Conclusions:
- Combined temozolomide and radiation therapy serves as a foundation for new treatment regimens.
- Enhanced understanding of tumor biology will enable targeted therapies.
- Personalized interventions based on specific patient and tumor characteristics are key to improving outcomes.
